Tag: Clinical trials

Search News
Categories
Archives
Immunotherapy significantly reduces recurrence in aggressive breast cancer

10th February 2022

An immunotherapy drug called ‘pembrolizumab’ has been shown to significantly reduce disease recurrence in patients with the most aggressive type of breast cancer, according to results from a phase III clinical trial led by Professor Peter Schmid from Queen Mary University of London and Barts Health NHS Trust.

Read more

Our Pancreatic Cancer Research: From BCI Bench to Bedside

18th November 2021

Pancreatic cancer is a core area of research focus at the Barts Cancer Institute, Queen Mary University of London, with a major aim being direct translation of laboratory research into clinical trials with the hope of improving outcomes for patients. Find out more this World Pancreatic Cancer Day.

Read more

London Pancreas Workshop 2020

30th September 2020

On 11th September 2020, Professors Hemant Kocher and Nick Lemoine hosted the eighth London Pancreas Workshop (LPW) – a forum for state-of-the-art clinical and basic research in pancreatic cancer. In a first for the biennial event, this year’s LPW took place online with pre-recorded speaker presentations and live, interactive Q&A sessions.

Read more

Results from the Phase I STARPAC trial

24th September 2020

A treatment combination involving the addition of a form of vitamin A to the current standard treatment regimen for pancreatic cancer is safe for patients, according to an early phase clinical trial led by Professor Hemant Kocher from Barts Cancer Institute, Queen Mary University of London.

Read more

Immunotherapy for advanced bladder cancer

18th September 2020

An immunotherapy drug called ‘avelumab’ has been shown to significantly improve survival in patients with the most common type of bladder cancer, according to results from a phase III clinical trial led by Professor Tom Powles.

Read more

Investigating new treatment options for mesothelioma

16th September 2020

Results from a phase I clinical trial led by Professor Peter Szlosarek were recently published in JTO Clinical and Research Reports. The trial was investigating the safety and efficacy of a new drug combination for the treatment of mesothelioma. We spoke to Professor Szlosarek to find out more about the trial, and how the drug combination may be able to help patients with mesothelioma.

Read more

Search News
Categories
Archives